Swedish player Iconovo is in line for larger future royalties through its partnership with Amneal covering a generic version of AstraZeneca’s Symbicort, after the two firms signed a new, expanded agreement.
Amneal’s collaboration agreement with Swedish inhalation specialist Iconovo to develop a generic version of AstraZeneca’s Symbicort (budesonide/formoterol) respiratory blockbuster “now covers approximately 90% of the total global Symbicort market,” after the two parties announced an extension to the initial partnership.
Around a year ago, Iconovo and Amneal agreed to terms to develop a generic rival to Symbicort in the Swedish...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
